京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002020 京新药业

已收盘 04-29 15:00:00

{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":14.94,"timestamp":1777446219000,"preClose":14.86,"halted":0,"volume":7173820,"delay":0,"changeRate":0.0054,"floatShares":724000000,"shares":861000000,"eps":0.8826,"marketStatus":"已收盘","change":0.08,"latestTime":"04-29 15:00:00","open":14.86,"high":15,"low":14.8,"amount":107000000,"amplitude":0.0135,"askPrice":14.94,"askSize":7,"bidPrice":14.93,"bidSize":55,"shortable":0,"etf":0,"ttmEps":0.8826,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777512600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.86,"symbolType":"stock","openAndCloseTimeList":[[1777426200000,1777433400000],[1777438800000,1777446000000]],"highLimit":16.35,"lowLimit":13.37,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.1,"roa":"--","peRate":16.92726,"roe":"2.76%","epsLYR":0.92,"committee":0.09418,"marketValue":12864000000,"turnoverRate":0.0099,"status":0,"floatMarketCap":10816000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2630324103","title":"【机构调研记录】浙商基金调研京新药业、我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2630324103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630324103?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:03","pubTimestamp":1777248184,"startTime":"0","endTime":"0","summary":"2）我武生物 调研纪要：公司2026年一季度营收利润增长，得益于销售管理优化与市场推广加强。浙商基金成立于2010年，截至目前，资产管理规模292.67亿元，排名105/212；资产管理规模213.59亿元，排名103/212；管理公募基金数74只，排名83/212；旗下公募基金经理14人，排名93/212。旗下最近一年表现最佳的公募基金产品为浙商智选经济动能混合A，最新单位净值为0.93，近一年增长54.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700007405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","002020","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630487800","title":"京新药业（002020）2026年一季报简析：净利润同比增长1.17%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2630487800","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630487800?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:22","pubTimestamp":1777069327,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期京新药业发布2026年一季报。截至本报告期末，公司营业总收入9.23亿元，同比下降3.46%，归母净利润1.65亿元，同比上升1.17%。本报告期京新药业盈利能力上升，毛利率同比增幅7.06%，净利率同比增幅4.06%。去年的净利率为18.84%，算上全部成本后，公司产品或服务的附加值高。2025 年，立项启动 15 项，注册申报 6项，注册获批 11项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500020591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629812621","title":"京新药业：公司降脂新药的对外授权工作在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2629812621","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629812621?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:45","pubTimestamp":1777023915,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：公司新药BD业务什么原因进展如此缓慢，二年了都没进展吗？京新药业回复：您好！公司降脂新药的对外授权工作在正常推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629814099","title":"京新药业：公司的盐酸卡立哌嗪胶囊在正常审批中","url":"https://stock-news.laohu8.com/highlight/detail?id=2629814099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629814099?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:42","pubTimestamp":1777023727,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司盐酸卡立哌嗪已移出申评任务公示栏两个多月，，药监局没有信息是不可能的。到底是获批了还是需要发补？京新药业回复：您好!公司的盐酸卡立哌嗪胶囊在正常审批中，公司25年底已经提交了补充的资料。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629854514","title":"图解京新药业年报：第四季度单季净利润同比增长33.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629854514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629854514?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:43","pubTimestamp":1776966236,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业2025年年报显示，当年度公司主营收入40.69亿元，同比下降2.14%；归母净利润7.58亿元，同比上升6.46%；扣非净利润7.12亿元，同比上升10.06%；其中2025年第四季度，公司单季度主营收入10.21亿元，同比上升7.51%；单季度归母净利润1.82亿元，同比上升33.16%；单季度扣非净利润1.74亿元，同比上升13.75%；负债率27.74%，投资收益1710.89万元，财务费用-4515.96万元，毛利率50.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400004249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627457410","title":"股市必读：京新药业（002020）4月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2627457410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627457410?lang=zh_cn&edition=full","pubTime":"2026-04-14 01:00","pubTimestamp":1776099644,"startTime":"0","endTime":"0","summary":"截至2026年4月13日收盘，京新药业报收于15.85元，下跌0.38%，换手率1.18%，成交量8.52万手，成交额1.35亿元。董秘最新回复投资者： 地达西尼韩国授权具体情况？地达西尼的对外授权工作在正常推进中，韩国暂未落地。公司已在2026年2月11日提交了H股上市的相关资料，目前正在排队审核中，具体情况敬请关注相关公告。当日关注点来自交易信息汇总：4月13日主力资金净流入43.79万元，显示主力小幅加仓。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400000768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627433092","title":"京新药业：地达西尼的销售工作正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2627433092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627433092?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:42","pubTimestamp":1776069739,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司地达西尼销售增长迅速，今年一季度业绩增长应该明显肥？京新药业回复：您好！地达西尼的销售工作正常推进中，相关销售情况敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300021063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627061433","title":"京新药业：公司已在2026年2月11日提交了H股上市的相关资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2627061433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627061433?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:42","pubTimestamp":1776069738,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司H股上市在中国证监会备案完成了吗？如未完成具体什么情况？京新药业回复：您好！公司已在2026年2月11日提交了H股上市的相关资料，目前正在排队审核中，具体情况敬请关注相关公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300021062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625938230","title":"京新药业：聚焦精神神经和心脑血管两大核心领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2625938230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625938230?lang=zh_cn&edition=full","pubTime":"2026-04-07 15:45","pubTimestamp":1775547911,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业04月07日在投资者关系平台上答复投资者关心的问题。是否应大力推介公司！谢谢您的建议，公司聚焦精神神经和心脑血管两大核心领域，对于盐酸卡立哌嗪等重要产品，公司会做好商业化承接工作，若顺利获批上市，会尽快推进其销售，给公司贡献利润。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700017123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622584933","title":"3月27日京新药业涨6.61%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622584933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622584933?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:15","pubTimestamp":1774599321,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日京新药业涨6.61%创60日新低，收盘报15.48元，换手率2.78%，成交量20.15万手，成交额3.05亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为30.94亿元，最新净值3.599，较上一交易日下跌0.8%，近一年上涨13.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622371528","title":"京新药业：2014年地衣芽孢杆菌活菌胶囊为国家重点新产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2622371528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622371528?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:27","pubTimestamp":1774513631,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月26日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司官网说公司国家重点单品8个，国家火炬项目9个。具体是指那几个药品？京新药业回复：您好！公司不同的产品获得了对应年份的国家重点新产品，例如2014年地衣芽孢杆菌活菌胶囊为国家重点新产品等；另外，2013年盐酸舍曲林及其制剂项目为国家火炬计划产业示范项目。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600029056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837145","title":"京新药业：目前盐酸卡立哌嗪胶囊审评工作在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622837145?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:27","pubTimestamp":1774513630,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月26日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕刚，公司重磅大单品盐酸卡立㖘嗪到底什么情况？怎么大的而且三年内独家重磅大单品公司是如何定位销售的如何推广为什么在投资者调研和互动都不正面回复？京新药业回复：您好！目前盐酸卡立哌嗪胶囊审评工作在进行中，希望可以尽快获批上市销售。同时，公司也会为未来获批后的销售工作做好承接。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600029055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837673","title":"京新药业：地达西尼的对外授权工作持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622837673?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:24","pubTimestamp":1774513450,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月26日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司官网说地达西尼已成功实现海外授权！为什么公司每次回复逐个推进。到底什么情况不敢公开授权情况？京新药业回复：您好！地达西尼的对外授权工作持续推进中，但是会首先推进可以相对快速上市地区的授权工作，这样可以快速给公司贡献收入和利润。具体情况敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600028779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621857770","title":"股市必读：京新药业（002020）今年截至3月23日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621857770","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621857770?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:22","pubTimestamp":1774290133,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，京新药业报收于14.4元，下跌4.76%，换手率2.06%，成交量14.93万手，成交额2.18亿元。当日关注点来自交易信息汇总：京新药业股价连续4日下跌，当日主力资金净流出1125.98万元，散户资金逆势净流入1977.22万元。交易信息汇总股价提醒3月23日京新药业收盘报14.4元，跌4.76%，当日成交1492.98万元。前10个交易日主力资金累计净流入3164.45万元，同期股价累计下跌6.03%；融资余额累计减少441.32万元，融券余量累计增加5100股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620012240","title":"京新药业：公司的盐酸卡立哌嗪胶囊审评工作持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620012240","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620012240?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:24","pubTimestamp":1773923048,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月19日在投资者关系平台上答复投资者关心的问题。投资者提问：请问盐酸卡利拉嗪胶囊还没有获批，是因为要发补吗？京新药业回复：您好！公司的盐酸卡立哌嗪胶囊审评工作持续推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900035658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424002","title":"京新药业：集采背景下仿制药价格调整对毛利率有一定影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620424002?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:24","pubTimestamp":1773923045,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月19日在投资者关系平台上答复投资者关心的问题。投资者提问：在集采下，京新阿司匹林只卖三分多钱一片，请问阿司匹林，瑞舒伐他汀，左乙拉西坦，舍曲林在集采下毛利大概多少？京新药业回复：您好！集采背景下，仿制药价格调整对毛利率有一定影响，但是，公司希望可以借助集采带来的机会，以价换量，保持业绩稳定增长。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900035651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253753","title":"京新药业：公司JX11502已经完成了临床II期","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620253753?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:18","pubTimestamp":1773836288,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问11502项目三期临床何时启动？何时结束京新药业回复：您好！公司JX11502已经完成了临床II期，相关情况敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800037461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620532212","title":"京新药业：目前盐酸卡立哌嗪胶囊审评工作在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620532212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620532212?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:15","pubTimestamp":1773836112,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司盐酸卡立哌嗪已通过技术审评达一个多月了，难道行政审批这么慢吗？京新药业回复：您好！目前盐酸卡立哌嗪胶囊审评工作在进行中，希望可以尽快获批上市销售。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800037359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253220","title":"京新药业：地达西尼的对外授权工作持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620253220?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:15","pubTimestamp":1773836109,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司官网几次说地达西尼已成功完成海外授权，而公司在互动易上却每次说正在推进中。问到底什么情况？为什么公司回答不一样？京新药业回复：您好！地达西尼的对外授权工作持续推进中，但是会首先推进可以相对快速上市地区的授权工作，这样可以快速给公司贡献收入和利润。具体情况敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800037356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618485709","title":"京新药业：公司的左乙拉西坦片已经经过几轮集采的续约","url":"https://stock-news.laohu8.com/highlight/detail?id=2618485709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618485709?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:24","pubTimestamp":1773221060,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问左乙拉西坦有没有中选最新一期国采京新药业回复：您好，公司的左乙拉西坦片已经经过几轮集采的续约。谢谢!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777461831845,"stockEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.0401},{"period":"3month","weight":-0.1228},{"period":"6month","weight":-0.1557},{"period":"1year","weight":0.1166},{"period":"ytd","weight":-0.2171}],"compareEarnings":[{"period":"1week","weight":-0.0016},{"period":"1month","weight":0.0421},{"period":"3month","weight":-0.0175},{"period":"6month","weight":0.023},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0277}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31813人(较上一季度减少79.43%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":"　　浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}